ArticlePloS one2026
PAH-former: Transfer learning for efficient discovery of pulmonary arterial hypertension-associated genes.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsPulmonary arterial hypertension (PAH) is a severe disease with limited effective therapies, making the discovery of new therapeutic targets crucial. While single-cell RNA sequencing (sc-RNA seq) offers a powerful tool for this purpose, its application is hampered by the scarcity of patient samples. This study addresses the problem of how to efficiently identify novel, functionally relevant disease-associated genes from limited publicly available data.
methodsWe employed transfer learning by fine-tuning Geneformer, a deep learning model, with public sc-RNA seq data from patients with PAH to create a specialized model called PAH-former. This model was used to perform in silico perturbation analysis to identify and rank candidate genes predicted to influence the disease state. For validation, we performed RNA interference-mediated knockdown of top novel candidate genes in human pulmonary artery endothelial cells and measured the expression of SRY-Box Transcription Factor 18 (SOX18), a signature gene of pulmonary arterial hypertension.
resultsIn silico perturbation analysis identified 134 candidate genes whose deletion was predicted to shift cells towards a disease phenotype. These included known disease-related genes as well as many novel ones. Subsequent in vitro validation demonstrated that knockdown of the candidate genes resulted in a significant increase in the expression of SOX18.
conclusionsOur novel platform, PAH-former, provides a powerful and broadly applicable strategy for disease-related gene discovery. This approach enables the identification and validation of new candidate genes from limited data, promising to advance cell-specific mechanistic insights and accelerate therapeutic development for rare diseases like PAH. (248/300 words).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.